UBS Group
TAK icon

UBS Group’s Takeda Pharmaceutical TAK Stock Holding History

UBS Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-780,100
Closed -$10.6M – 10877
2021
Q4 		$10.6M Buy
780,100
+682,600
+700% +$9.58M ﹤0.01% 2088
2021
Q3 		$1.6M Hold
97,500
– – ﹤0.01% 3782
2021
Q2 		$1.64M Hold
97,500
– – ﹤0.01% 3750
2021
Q1 		$1.78M Buy
+97,500
New +$1.75M ﹤0.01% 3673

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

UBS Group's TAK Position: Q2 2026 in Review

UBS Group reduced its Takeda Pharmaceutical (TAK) stake by 67% in Q2 2026, selling an estimated $30.3M and leaving 911,319 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3017.

UBS Group first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $171M in Q4 2018. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • UBS Group held 911,319 shares of Takeda Pharmaceutical worth $14.6M as of Q2 2026.
  • UBS Group sold 1,828,910 Takeda Pharmaceutical shares in Q2 2026, an estimated $30.3M.
  • Takeda Pharmaceutical made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3017 holding.
  • UBS Group first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
  • UBS Group's Takeda Pharmaceutical position peaked at $171M in Q4 2018.
  • 378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.